Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

A systematic analysis of atomic protein-ligand interactions in the PDB.

Ferreira de Freitas R, Schapira M.

Medchemcomm. 2017 Oct 1;8(10):1970-1981. doi: 10.1039/c7md00381a. Epub 2017 Sep 26.

2.

Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT.

Rempel BP, Price EW, Phenix CP.

Mol Imaging. 2017 Jan-Dec;16:1536012117717852. doi: 10.1177/1536012117717852.

3.

Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening.

Temml V, Garscha U, Romp E, Schubert G, Gerstmeier J, Kutil Z, Matuszczak B, Waltenberger B, Stuppner H, Werz O, Schuster D.

Sci Rep. 2017 Feb 20;7:42751. doi: 10.1038/srep42751.

4.

Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.

Bungard CJ, Williams PD, Ballard JE, Bennett DJ, Beaulieu C, Bahnck-Teets C, Carroll SS, Chang RK, Dubost DC, Fay JF, Diamond TL, Greshock TJ, Hao L, Holloway MK, Felock PJ, Gesell JJ, Su HP, Manikowski JJ, McKay DJ, Miller M, Min X, Molinaro C, Moradei OM, Nantermet PG, Nadeau C, Sanchez RI, Satyanarayana T, Shipe WD, Singh SK, Truong VL, Vijayasaradhi S, Wiscount CM, Vacca JP, Crane SN, McCauley JA.

ACS Med Chem Lett. 2016 May 9;7(7):702-7. doi: 10.1021/acsmedchemlett.6b00135. eCollection 2016 Jul 14.

5.

18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase.

Horti AG, Wang Y, Minn I, Lan X, Wang J, Koehler RC, Alkayed NJ, Dannals RF, Pomper MG.

J Nucl Med. 2016 Nov;57(11):1817-1822. Epub 2016 Jul 14.

6.

Single-residue posttranslational modification sites at the N-terminus, C-terminus or in-between: To be or not to be exposed for enzyme access.

Sirota FL, Maurer-Stroh S, Eisenhaber B, Eisenhaber F.

Proteomics. 2015 Jul;15(14):2525-46. doi: 10.1002/pmic.201400633.

7.

Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Kim IH, Lee IH, Nishiwaki H, Hammock BD, Nishi K.

Bioorg Med Chem. 2014 Feb 1;22(3):1163-75. doi: 10.1016/j.bmc.2013.12.027. Epub 2014 Jan 3.

8.

Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.

Morisseau C, Pakhomova S, Hwang SH, Newcomer ME, Hammock BD.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3818-21. doi: 10.1016/j.bmcl.2013.04.083. Epub 2013 May 6.

9.

Förster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase.

Lee KS, Morisseau C, Yang J, Wang P, Hwang SH, Hammock BD.

Anal Biochem. 2013 Mar 15;434(2):259-68. doi: 10.1016/j.ab.2012.11.015. Epub 2012 Dec 5.

10.

Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.

Morisseau C, Hammock BD.

Annu Rev Pharmacol Toxicol. 2013;53:37-58. doi: 10.1146/annurev-pharmtox-011112-140244. Epub 2012 Sep 27. Review.

11.

Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Shen HC, Hammock BD.

J Med Chem. 2012 Mar 8;55(5):1789-808. doi: 10.1021/jm201468j. Epub 2012 Jan 17. Review. No abstract available.

12.

1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.

Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y, Do ZN, Mehra U, Tran V, Vincelette J, Waszczuk J, White K, Wong KR, Zhang LN, Jones PD, Hammock BD, Patel DV, Whitcomb R, MacIntyre DE, Sabry J, Gless R.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):983-8. doi: 10.1016/j.bmcl.2010.12.042. Epub 2010 Dec 13.

13.

Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Huang SX, Li HY, Liu JY, Morisseau C, Hammock BD, Long YQ.

J Med Chem. 2010 Dec 9;53(23):8376-86. doi: 10.1021/jm101087u. Epub 2010 Nov 11.

14.

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, Hammock BD.

J Med Chem. 2010 Oct 14;53(19):7067-75. doi: 10.1021/jm100691c.

Supplemental Content

Support Center